Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07100990 · ClinicalTrials.gov registry record · Phase 3

Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)

A Phase 3 study of Optic Neuritis and Myelitis, Transverse, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 3
Development phase
382
Enrollment target
20
Study locations

NCT07100990: Recruiting Phase 3 study of Optic Neuritis and Myelitis, Transverse, sponsored by Mayo Clinic.

NCT07100990 is a Phase 3 study of Optic Neuritis and Myelitis, Transverse that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 382 participants, below the 728-participant average among 5 other Optic Neuritis trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07100990, a Phase 3 study of Optic Neuritis and Myelitis, Transverse, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 3
Development phase
382 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this research is to evaluate if early vs rescue Therapeutic Plasma Exchange (PLEX) treatment algorithm leads to better visual outcomes in severe Optic Neuritis and leads to better neurological disability outcomes in severe Transverse Myelitis.

Primary Outcome

The Optic Neuritis subjects will have high contrast visual acuity measured by ETDRS 100% high-contrast Sloan letter charts. A high contrast visual acuity of 20/20 is considered "normal," a high contrast visual acuity of 20/40 or better is required to be able to drive without restrictions, and a high contrast visual acuity of 20/200 or worse is considered legally blind.

Interventions

  • DRUG High-dose corticosteroids (HDCS)
  • DRUG High-dose corticosteroids (HDCS) and PLEX

Study Locations (20)

Illinois

  • University of Illinois Chicago - Chicago
  • Northwestern University - Evanston

Maryland

  • University of Maryland, Baltimore - Baltimore
  • Johns Hopkins University - Baltimore

Massachusetts

  • Harvard University Massachusetts General Hospital - Boston
  • Boston Medical Center - Boston

New York

  • Icahn School of Medicine at Mount Sinai - New York
  • Weill Cornell Medical College - New York

Arizona

  • Mayo Clinic Arizona - Scottsdale

Colorado

  • University of Colorado - Anschutz Medical - Aurora

Connecticut

  • Yale University School of Medicine - North Haven

Florida

  • Mayo Clinic Florida - Jacksonville

Trial Details

FieldValue
Enrollment Target 382 participants
Start Date 2025-07-11
Est. Completion 2031-04-30
Phase Phase 3
Mayo Clinic

2,844 total trials

What NCT07100990 shows while recruiting

NCT07100990 is an interventional study that assigns participants to a tested intervention. The registered 382 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 5 other Optic Neuritis trials with a reported enrollment target (48% lower).

The record links to 3 conditions, with Optic Neuritis appearing as the primary indexed condition, and to 2 interventions - of which High-dose corticosteroids (HDCS) is the first listed.

NCT07100990 names 20 study sites across 16 states, led by Illinois, Maryland, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT07100990 about?

NCT07100990 is a clinical study titled "Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)". The purpose of this research is to evaluate if early vs rescue Therapeutic Plasma Exchange (PLEX) treatment algorithm leads to better visual outcomes in severe Optic Neuritis and leads to better neurological disability outcomes in severe Transverse Myelitis.

What is the current status of trial NCT07100990?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 382 participants. The study started on 2025-07-11. Estimated completion is 2031-04-30.

What conditions does trial NCT07100990 study?

This clinical trial studies the following conditions: Optic Neuritis, Myelitis, Transverse, Myelitis.

What interventions are being tested in trial NCT07100990?

The interventions under investigation include: High-dose corticosteroids (HDCS) (DRUG), High-dose corticosteroids (HDCS) and PLEX (DRUG).

Who is sponsoring clinical trial NCT07100990?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07100990 being conducted?

This trial has 20 study locations across Arizona, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Optic Neuritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05677490 · 382 participants · Phase 3

    mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

  • NCT06196008 · 382 participants · NA

    Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers

  • NCT06056830 · 383 participants · Phase 3

    Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  • NCT06277661 · 384 participants · NA

    The Mom and Infant Outcomes (MOMI) Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07100990, the US trial registry maintained by the National Library of Medicine. NCT07100990 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.